In last trading session, Kintara Therapeutics Inc (NASDAQ:KTRA) saw 2.07 million shares changing hands with its beta currently measuring 0.56. Company’s recent per share price level of $0.09 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $3.52M. That closing price of KTRA’s stock is at a discount of -6544.44% from its 52-week high price of $5.98 and is indicating a premium of 11.11% from its 52-week low price of $0.08. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 19.62 million shares which gives us an average trading volume of 13.26 million if we extend that period to 3-months.
Kintara Therapeutics Inc (NASDAQ:KTRA) trade information
In the last five days KTRA remained trading in the red while hitting it’s week-highest on Thursday, 03/14/24 when the stock touched $0.09 price level, adding 24.37% to its value on the day. Kintara Therapeutics Inc’s shares saw a change of -46.87% in year-to-date performance and have moved -26.21% in past 5-day. Kintara Therapeutics Inc (NASDAQ:KTRA) showed a performance of -8.06% in past 30-days. Number of shares sold short was 2.19 million shares which calculate 0.18 days to cover the short interests.
Kintara Therapeutics Inc (KTRA) estimates and forecasts
Statistics highlight that Kintara Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -97.75% of value to its shares in past 6 months, showing an annual growth rate of 73.25% while that of industry is 12.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 49.09% during past 5 years.
KTRA Dividends
Kintara Therapeutics Inc is more likely to be releasing its next quarterly report between May 09 and May 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Kintara Therapeutics Inc (NASDAQ:KTRA)’s Major holders
Insiders are in possession of 0.21% of company’s total shares while institution are holding 0.62 percent of that, with stock having share float percentage of 0.62%. Investors also watch the number of corporate investors in a company very closely, which is 0.62% institutions for Kintara Therapeutics Inc that are currently holding shares of the company. Geode Capital Management, LLC is the top institutional holder at KTRA for having 14036.0 shares of worth $56565.0. And as of Jun 29, 2023, it was holding 0.80% of the company’s outstanding shares.
The second largest institutional holder is State Street Corporation, which was holding about 10721.0 shares on Jun 29, 2023. The number of shares represents firm’s hold over 0.61% of outstanding shares, having a total worth of $43205.0.
On the other hand, Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of May 30, 2023, the former fund manager was holding 9104.0 shares of worth $29223.0 or 0.52% of the total outstanding shares. The later fund manager was in possession of 7563.0 shares on Jun 29, 2023, making its stake of worth around $30478.0 in the company or a holder of 0.43% of company’s stock.
